A Novel Ammonium Carboxylate Salt of Undecylenic Acid for the Topical Treatment of Gram‐Positive and Antibiotic‐Resistant Skin Infections
Experimental Dermatology · 2025
DOI: 10.1111/exd.70075 ↗At a glance
Journal article in Experimental Dermatology, 2025. Written by Alyce Mayfosh and 1 co-authors. Institution: Wintermute Biomedical Inc., Missoula, Montana, USA. Major MEDLINE topics: Anti-Bacterial Agents, Arginine. Cited 1 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Uncomplicated topical skin infections like impetigo, caused by gram‐positive bacteria such as Staphylococcus aureus and Streptococcus pyogenes , are a common global health issue, particularly affecting children. With increasing antimicrobial resistance, conventional treatments such as mupirocin are becoming ineffective, highlighting the necessity for new antimicrobial development. Fatty acids have long shown potential as novel antimicrobials, but their development has been limited by solubility and efficacy concerns in topical applications. We previously discovered that combining the amino acid L‐arginine with an 11‐carbon fatty acid, undecylenic acid, produced a water‐soluble ammonium carboxylate salt, arginine undecylenate, referred to as GS‐1, that elicits potent antimicrobial activity. Under CLSI test conditions, GS‐1 showed effective antibacterial activity against clinical isolates of methicillin‐sensitive S. aureus (MSSA), methicillin‐resistant S. aureus (MRSA), vancomycin‐intermediate S. aureus , and S. pyogenes , with MICs of 0.60–1.26 mg/mL and MBCs of 0.63–5.04 mg/mL, respectively. Fluorescence microscopy revealed GS‐1 to elicit antibacterial activity by rapidly permeabilising bacterial membranes and inducing reactive oxygen species formation. Serial exposure of 5 MRSA clinical isolates to sub‐lethal doses of GS‐1 did not appear to induce resistance. In fact, compared to mupirocin, repeated exposures to GS‐1 appeared to sensitise bacteria to GS‐1. In an animal model of skin infection, topical GS‐1 successfully eradicated MRSA from infected, abraded skin after 6 days of treatment with no signs of toxicity. Finally, repeated topical GS‐1 exposure in humans caused no irritation or sensitisation. These results support GS‐1 as a potential novel topical antibacterial for the treatment of impetigo and other skin infections.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Wintermute Biomedical Inc., Missoula, Montana, USA.
ORCID profiles: Alyce Mayfosh
Cite
APA
Mayfosh, A., & Rau, T. (2025). A Novel Ammonium Carboxylate Salt of Undecylenic Acid for the Topical Treatment of Gram‐Positive and Antibiotic‐Resistant Skin Infections. Experimental Dermatology. https://doi.org/10.1111/exd.70075
Vancouver
Mayfosh A, Rau T. A Novel Ammonium Carboxylate Salt of Undecylenic Acid for the Topical Treatment of Gram‐Positive and Antibiotic‐Resistant Skin Infections. Experimental Dermatology. 2025. doi:10.1111/exd.70075
BibTeX
@article{Mayfosh2025,
author = {Mayfosh, Alyce and Rau, Thomas},
title = {A Novel Ammonium Carboxylate Salt of Undecylenic Acid for the Topical Treatment of Gram‐Positive and Antibiotic‐Resistant Skin Infections},
journal = {Experimental Dermatology},
year = {2025},
doi = {10.1111/exd.70075}
}
EUVIMED